In a breakthrough that could transform life for millions, researchers at the University of Missouri School of Medicine have developed a way to protect transplanted pancreatic islets from immune rejection without forcing patients into a lifetime of immunosuppressive drugs.
Type 1 diabetes is a relentless autoimmune condition—the body's own immune system attacks insulin-producing cells in the pancreas, leaving patients dependent on insulin injections to survive. A promising treatment exists: transplanting healthy islets from donors to replace what the immune system has destroyed. But there's been a stubborn catch: recipients must take medications that suppress their entire immune system to prevent the body from rejecting the transplant, and those drugs weaken the body in ways that create their own set of problems.
The University of Missouri team found a different path. Rather than asking the immune system to stand down globally, they engineered a protective "shield" for the transplanted islets using two specific immune-regulating molecules: thrombomodulin and CD47. Thrombomodulin prevents the harmful inflammation that would otherwise trigger early destruction of the transplanted cells. CD47 sends a signal to immune cells, essentially telling them there's no threat and to back off.
The results were striking. In a preclinical model, over 72% of transplant recipients achieved normal blood sugar levels without needing insulin medication. When islets carried both molecules, survival rates far exceeded those of islets with just one. The transplanted cells could respond naturally to glucose and secrete insulin as they should—the body wasn't rejecting them, and patients weren't taking immune-dampening drugs with widespread side effects.
Study author Haval Shirwan explained the thinking: "Immunosuppressant medications affect and weaken the whole body, so we instead focused on how we could improve our delivery of the transplanted islets." His colleague Esma Yolcu added that the engineered islets with both molecules achieved "a far better survival rate than islets with only one."
The timing matters. Approximately 2 million Americans currently live with type 1 diabetes, and that number is rising as disease rates climb. For these patients—many of them children and young adults—the prospect of eliminating insulin shots and the daily management burden is profound. "If future research trials succeed, this transplantation treatment could help patients with T1D manage their symptoms and eliminate the need for insulin shots," the researchers noted.
The work, published in JCI Insight, remains in preclinical stages. The team emphasizes the need for further research to confirm safety and effectiveness in humans. But Shirwan's words capture the promise: "This method is a promising way to stabilize T1D."
What makes this advance distinctive is its elegance. Rather than asking the immune system to surrender, the researchers engineered a solution that lets transplanted cells integrate peacefully—a retraining of the immune system at the local level rather than systemic suppression. If the human trials ahead confirm what the preclinical work suggests, it could reshape how type 1 diabetes is managed, turning a lifelong dependency into a one-time transplant that restores the body's natural insulin production.